Searchable abstracts of presentations at key conferences in endocrinology

ea0025p102 | Clinical biochemistry | SFEBES2011

Hyponatraemia and SIADH as a presenting feature of acquired immunodeficiency syndrome

Cousland Zoe , Payne Chris , El-Mahmoudi Bashir

A 59-year-old Caucasian heterosexual man presented with malaise and dizziness. General examination revealed no peripheral oedema, no clubbing or lymphadenopathy and systemic examination was otherwise normal. His initial investigations showed hyponatremia with serum sodium 121 mmol/l, potassium 3.4 mmol/, serum osmolality 255 mOsml/kg, and urine osmolality 672 mOsml/kg. The rest of blood tests including; thyroid function, short Synacthen test, full blood count, liver functions,...

ea0077oc5.6 | Bone and Calcium | SFEBES2021

The role of vitamin D supplementation in critically ill patients with COVID-19

Hoskyns Samuel , Payne-Doris Thomas , Hardy Gavin , Bain Robert

Background: Studies have established a link between vitamin D deficiency and susceptibility to and severity of COVID-19. Our study aims to evaluate the role of vitamin D supplementation in intensive care units (ICU) in patients with COVID-19.Methods: We conducted a retrospective analysis of patients admitted to ICU in a large tertiary centre. Data on serum vitamin D concentration and supplementation, mortality, hospital and ICU stay, electrolyte replacem...

ea0050p247 | Neoplasia, Cancer and Late Effects | SFEBES2017

Check point inhibitor monoclonal antibody therapy – Are there effective markers for endocrine immune-related adverse events?

Anguelova Lia , Dhere Archana , Payne Miranda , Turner Helen

Introduction: Whilst effective, targeted checkpoint inhibitor monoclonal antibodies are associated with immune-related adverse events including endocrinopathies. Increased licensed oncological indications for these agents raise the need for effective screening, monitoring and ongoing treatment of endocrinopathies. The aim of our study was to investigate potential predictive factors that may identify patients at risk of endocrinopathies....

ea0050p247 | Neoplasia, Cancer and Late Effects | SFEBES2017

Check point inhibitor monoclonal antibody therapy – Are there effective markers for endocrine immune-related adverse events?

Anguelova Lia , Dhere Archana , Payne Miranda , Turner Helen

Introduction: Whilst effective, targeted checkpoint inhibitor monoclonal antibodies are associated with immune-related adverse events including endocrinopathies. Increased licensed oncological indications for these agents raise the need for effective screening, monitoring and ongoing treatment of endocrinopathies. The aim of our study was to investigate potential predictive factors that may identify patients at risk of endocrinopathies....

ea0065p141 | Endocrine Neoplasia and Endocrine Consequences of Living with and Beyond Cancer | SFEBES2019

Predicting hypophysitis in patients treated with immune checkpoint inhibitors: can prolactin be used as a marker of incipient disease?

Noronha Sean , Pueyo Maria , Payne Miranda , Turner Helen

Background: Immune checkpoint inhibitors (ICIs), approved in the UK for the treatment of increasingly numerous malignancies, are commonly associated with endocrine sequelae, some of which may be life threatening. Society for Endocrinology guidelines detail management protocols for acute endocrinopathies, however widely accepted standards for their routine detection are lacking. Hypophysitis, clinically and radiologically silent in many, is seen in up to 15% of patients on ICIs...

ea0010p59 | Pituitary | SFE2005

Inhibitors of the ABCA1 transporter affect annexin 1 release in the TtT/GF folliculostellate cell line

Payne J , Morris J , Solito E , Buckingham J

Acknowledgements: This work was generously supported by the Wellcome TrustAnnexin 1 (ANXA1) plays an important role in mediating the negative feedback effects of glucocorticoids on the HPA axis. It is released from non-secretory folliculostellate (FS) cells by glucocorticoids and acts locally to suppress ACTH release from corticotrophs. Previous studies suggest that the steroid-induced translocation of ANXA1 across the FS cell membrane is effected via me...

ea0009oc22 | Oral Communication 3: Neuroendocrinology | BES2005

Modulators of the SUR2B/Kir6.1 ATP-sensitive K+ channel regulate annexin 1 release in the TtT/GF folliculostellate cell line

Payne J , Morris J , Solito E , Buckingham J

Annexin 1 (ANXA1) plays an important role in mediating the negative feedback effects of glucocorticoids on the HPA axis. In the anterior pituitary gland ANXA1 is localised mainly to the non-secretory folliculostellate (FS) cells. It is released from these cells by glucocorticoids and acts locally to suppress ACTH release from corticotrophs. Functional and histological studies suggest that the steroid-induced translocation of ANXA1 across the FS cell membrane is effected via me...

ea0006oc18 | Growth and Development | SFE2003

Testosterone 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activities of mouse type I and VI 3beta-hydroxysteroid dehydrogenases

Howe B , Howie A , Morley S , Payne A , Mason J

3beta-hydroxysteroid dehydrogenase (3beta-HSD) expression is essential for the synthesis of all classes of steroid hormones, converting delta5beta-hydroxysteroids into hormonally active delta4-3-ketosteroids in NAD+-dependent reactions. Numerous 3beta-HSD isoforms have been described in mouse, rat, human and other mammals, all with distinct tissue and developmentally specific expression, distinct kinetics, with alternative substrate specificity...

ea0081oc11.5 | Oral Communications 11: Thyroid 2 | ECE2022

Positive correlation of thyroid nodule cytology with molecular profiling – analysis of over 4000 nodules from multicenter study and systematic literature review

Tessler Idit , Shochat Isaac , Cohen Oded , Payne Richard J , Avior Galit

Objectives: Despite the increasing role of molecular profiling, the association between mutation expression and pre-operative cytology for thyroid nodules has not been established.Methods: We collected data on patients who underwent molecular profiling of thyroid nodules in Bethesda categories III to VI from two tertiary academic hospitals and via systematic literature review. We tested the associations between Bethesda categories and molecular mutation ...

ea0027p51 | (1) | BSPED2011

Continuing variation in DKA guidelines despite national guidelines

Messazos Betty , Payne Susan , Ackland Frances , McAuley Antoinette , Hind Ed , Burren Christine , Edge Julie

Since the introduction of national BSPED DKA guidelines we wondered whether the previous variability in DKA guidelines would be abolished.Aim: To explore the variability of guidelines in three regional diabetes networks in South West (SW) and South Central England and to compare them to the current BSPED guidelines.Methods: Within an audit of in-patient care, a copy of the DKA guidelines was requested from 27 services. General layo...